Stem definition | Drug id | CAS RN |
---|---|---|
antibiotics, cefalosporanic acid derivatives | 526 | 50370-12-2 |
Dose | Unit | Route |
---|---|---|
2 | g | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 14.20 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 93 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 78.62 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 95 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 0.23 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 2.50 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.39 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 1.10 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Feb. 17, 1978 | FDA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Type IV hypersensitivity reaction | 262.18 | 23.70 | 48 | 1356 | 2492 | 46682166 |
Rash maculo-papular | 127.80 | 23.70 | 43 | 1361 | 27831 | 46656827 |
Oedema | 64.43 | 23.70 | 34 | 1370 | 67037 | 46617621 |
Drug hypersensitivity | 53.98 | 23.70 | 50 | 1354 | 243775 | 46440883 |
Veillonella infection | 28.44 | 23.70 | 4 | 1400 | 36 | 46684622 |
Drug reaction with eosinophilia and systemic symptoms | 28.35 | 23.70 | 15 | 1389 | 29533 | 46655125 |
Neisseria infection | 27.63 | 23.70 | 4 | 1400 | 45 | 46684613 |
Cellulitis | 24.94 | 23.70 | 19 | 1385 | 70269 | 46614389 |
Stomatococcal infection | 24.70 | 23.70 | 4 | 1400 | 98 | 46684560 |
Immunodeficiency common variable | 24.09 | 23.70 | 4 | 1400 | 115 | 46684543 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|
Source | Code | Description |
---|---|---|
ATC | J01DB05 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS First-generation cephalosporins |
CHEBI has role | CHEBI:36047 | antibacterial drugs |
MeSH PA | D000900 | Anti-Bacterial Agents |
MeSH PA | D000890 | Anti-Infective Agents |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Infection of skin AND/OR subcutaneous tissue | indication | 19824006 | |
Streptococcal tonsillitis | indication | 41582007 | |
Klebsiella cystitis | indication | 60867007 | |
Urinary tract infectious disease | indication | 68566005 | |
Tonsillitis | indication | 90176007 | DOID:10456 |
Escherichia coli urinary tract infection | indication | 301011002 | |
Proteus urinary tract infection | indication | 301012009 | |
Streptococcus pyogenes infection | indication | 302809008 | |
Infection due to Staphylococcus aureus | indication | 406602003 | |
Prevention of Bacterial Endocarditis | off-label use | ||
Impaired renal function disorder | contraindication | 197663003 | |
Pseudomembranous enterocolitis | contraindication | 397683000 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 2.77 | acidic |
pKa2 | 9.72 | acidic |
pKa3 | 13.53 | acidic |
pKa4 | 7.63 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Solute carrier family 15 member 1 | Transporter | Ki | 2.14 | WOMBAT-PK | |||||
Bacterial penicillin-binding protein | Enzyme | INHIBITOR | CHEMBL | CHEMBL |
ID | Source |
---|---|
4018151 | VUID |
N0000146488 | NUI |
D00257 | KEGG_DRUG |
66592-87-8 | SECONDARY_CAS_RN |
4018151 | VANDF |
C0007538 | UMLSCUI |
CHEBI:53667 | CHEBI |
CHEMBL1644 | ChEMBL_ID |
DB01140 | DRUGBANK_ID |
D002434 | MESH_DESCRIPTOR_UI |
47965 | PUBCHEM_CID |
4831 | IUPHAR_LIGAND_ID |
280111G160 | UNII |
1297878 | RXNORM |
d00080 | MMSL |
004959 | NDDF |
13414000 | SNOMEDCT_US |
372651006 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-3196 | CAPSULE | 500 mg | ORAL | ANDA | 22 sections |
Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-4059 | TABLET | 1000 mg | ORAL | ANDA | 23 sections |
Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9766 | POWDER, FOR SUSPENSION | 500 mg | ORAL | ANDA | 21 sections |
Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9767 | POWDER, FOR SUSPENSION | 250 mg | ORAL | ANDA | 21 sections |
Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9947 | CAPSULE | 500 mg | ORAL | ANDA | 21 sections |
Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9948 | TABLET, FILM COATED | 1 g | ORAL | ANDA | 23 sections |
Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-135 | CAPSULE | 500 mg | ORAL | ANDA | 19 sections |
CEFADROXIL | Human Prescription Drug Label | 1 | 16590-043 | CAPSULE | 500 mg | ORAL | ANDA | 23 sections |
Cefadroxil | Human Prescription Drug Label | 1 | 16714-388 | CAPSULE | 500 mg | ORAL | ANDA | 21 sections |
Cefadroxil | Human Prescription Drug Label | 1 | 16714-389 | POWDER, FOR SUSPENSION | 250 mg | ORAL | ANDA | 21 sections |
Cefadroxil | Human Prescription Drug Label | 1 | 16714-390 | POWDER, FOR SUSPENSION | 500 mg | ORAL | ANDA | 21 sections |
Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-427 | CAPSULE | 500 mg | ORAL | ANDA | 22 sections |
Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 33261-018 | CAPSULE | 500 mg | ORAL | ANDA | 19 sections |
Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42254-146 | CAPSULE | 500 mg | ORAL | ANDA | 19 sections |
CEFADROXIL | Human Prescription Drug Label | 1 | 42549-504 | CAPSULE | 500 mg | ORAL | ANDA | 23 sections |
Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43063-553 | CAPSULE | 500 mg | ORAL | ANDA | 19 sections |
Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43063-595 | CAPSULE | 500 mg | ORAL | ANDA | 21 sections |
Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 45865-503 | CAPSULE | 500 mg | ORAL | ANDA | 19 sections |
Cefadroxil | Human Prescription Drug Label | 1 | 50090-1915 | CAPSULE | 500 mg | ORAL | ANDA | 21 sections |
Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 52959-428 | CAPSULE | 500 mg | ORAL | ANDA | 19 sections |
Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 53002-2290 | CAPSULE | 500 mg | ORAL | ANDA | 19 sections |
Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-3742 | CAPSULE | 500 mg | ORAL | ANDA | 13 sections |
Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-5693 | POWDER, FOR SUSPENSION | 250 mg | ORAL | ANDA | 14 sections |
Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-5694 | POWDER, FOR SUSPENSION | 500 mg | ORAL | ANDA | 14 sections |
Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55289-589 | CAPSULE | 500 mg | ORAL | ANDA | 21 sections |
Cefadroxil | Human Prescription Drug Label | 1 | 57237-096 | CAPSULE | 500 mg | ORAL | ANDA | 21 sections |
Cefadroxil | Human Prescription Drug Label | 1 | 57237-097 | POWDER, FOR SUSPENSION | 250 mg | ORAL | ANDA | 21 sections |
Cefadroxil | Human Prescription Drug Label | 1 | 57237-098 | POWDER, FOR SUSPENSION | 500 mg | ORAL | ANDA | 21 sections |
Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 57297-180 | CAPSULE | 500 mg | ORAL | ANDA | 19 sections |
Cefadroxil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63187-883 | CAPSULE | 500 mg | ORAL | ANDA | 19 sections |